Our data suggest that EGFR TaqMan Mutation Detection Assays powered by castPCR technology are a robust method that has shown an adequate sensitivity and specificity to detect clinically relevant EGFR mutations in samples from NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.